Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 17:00 save search
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.78 -2.25% -2.3% 270K
|
Health Technology
|
| O: -2.27%
H: 0.0%
C: 0.0%
positive treatment results study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $397.48 0.24% 0.23% 1.4M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Published: 2024-03-26 (Crawled : 17:00) - biospace.com/
PSNL | $1.265 -0.78% -0.79% 270K
|
Health Technology
|
| O: 4.17%
H: 2.0%
C: -4.67%
personal test cancer publication treatment response
Myopia and presbyopia treatment market size to grow by USD 7.94 billion from 2022 to 2027, Major Vendors include AbbVie Inc., Alcon Inc. and Arctic Vision, Technavio
Published: 2024-02-28 (Crawled : 17:00) - prnewswire.com
FNCTF | $11.128 -20.84% 580
|
Communications
|
| O: -1.4%
H: 0.0%
C: -0.01%
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: 0.11%
H: 2.23%
C: 0.11%
ALC | $81.09 -0.23% 0.0% 690K
|
Health Technology
|
| O: 4.09%
H: 1.72%
C: 1.41%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
abbvie presbyopia treatment market
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO A | $30.13 -0.63% 0.0% 1.7M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More than a Decade
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO A | $30.13 -0.63% 0.0% 1.7M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
FDA Decisions: Agency Greenlights Takeda's Oral EoE Treatment in Company's Se...
Published: 2024-02-12 (Crawled : 17:00) - biospace.com/
PRGO A | $30.13 -0.63% 0.0% 1.7M
|
Health Technology
|
| O: 0.31%
H: 1.44%
C: 1.31%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
fda treatment
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Published: 2024-02-02 (Crawled : 17:00) - globenewswire.com
SYBX | $1.79 1.13% 1.12% 38K
|
Health Technology
|
| O: -0.29%
H: 4.02%
C: -2.01%
synb1353 publication treatment preclinical potential
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: -6.38%
H: 0.88%
C: 0.88%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.09%
H: 0.17%
C: -0.3%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.58%
H: 1.01%
C: -0.58%
keytruda bladder cancer treatment application advanced
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
Published: 2024-01-03 (Crawled : 17:00) - biospace.com/
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: -0.06%
H: 1.75%
C: 1.54%
million treatment
Perma-Fix Joint Venture Receives Formal Award of European Waste Treatment Contract Valued at up to EUR 50 Million
Published: 2023-12-21 (Crawled : 17:00) - globenewswire.com
PESI | $11.23 -6.03% -6.41% 60K
|
Industrial Services
|
| O: 0.0%
H: 4.85%
C: -1.57%
award contract million treatment
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Published: 2023-12-08 (Crawled : 17:00) - globenewswire.com
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 0.0%
H: 8.02%
C: -0.94%
cure cancer treatment pharmaceuticals
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
COYA | $8.3 -7.98% -8.67% 75K
|
|
| O: 5.91%
H: 3.76%
C: -6.1%
sclerosis treatment collaboration commercialization therapy
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or AnxietyGrant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property Portfolio
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
AVXL | $4.23 -1.51% -1.54% 1.1M
|
Health Technology
|
| O: 0.6%
H: 1.88%
C: -0.89%
anavex patent blarcamesine life treatment sciences grant
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
Published: 2023-10-11 (Crawled : 17:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.45%
H: 0.52%
C: -0.94%
opzelura treatment program
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
CGEN | $1.95 -8.45% -9.23% 750K
|
Health Technology
|
| O: 0.0%
H: 6.45%
C: 3.23%
patent antibody cancer treatment
Global HIV Drugs Market Research Report 2023-2031: Long-Acting Injectable HIV Therapies Redefining the Treatment Landscape
Published: 2023-10-02 (Crawled : 17:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.05%
H: 0.09%
C: -0.28%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
report treatment research global hiv market
Walgreens, AllianceRx Walgreens Pharmacy Study of Non-Infused Biologics in Rheumatoid Arthritis Treatment Underscores Importance of Medication Adherence
Published: 2023-09-20 (Crawled : 17:00) - prnewswire.com
WBA | $17.655 -1.09% -1.1% 10M
|
Retail Trade
|
| O: -0.09%
H: 0.95%
C: -0.77%
treatment study
Mon Power and Potomac Edison Improve Wastewater Treatment Process at West Virginia Power Plants
Published: 2023-09-11 (Crawled : 17:00) - prnewswire.com
FE | $37.4 -0.03% 0.0% 2.6M
|
Utilities
|
| O: 0.06%
H: 0.95%
C: -0.17%
plants west treatment
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.